MedPath

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

Phase 2
Terminated
Conditions
Epilepsy
Interventions
Registration Number
NCT02316847
Lead Sponsor
Acorda Therapeutics
Brief Summary

This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
126
Inclusion Criteria
  • Diagnosis of drug-resistant epilepsy
  • Patients who experience multiple episodes of acute repetitive seizures requiring at least one concomitant antiepileptic drug (AED)
  • Occurrence of at least 3 seizure clusters within the past 12 months, including at least one cluster in the 4 months prior to the Screening Visit
  • A caregiver must consent to participate together with the subject for purposes of observation and data collection
  • The caregiver must be present when the investigational product is administered
  • Screening body weight between 26 to 111 kg, inclusive
Exclusion Criteria
  • Female subject who is pregnant, breastfeeding, or planning to become pregnant
  • Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam
  • Known allergy or hypersensitivity to diazepam, related drugs, or any of the formulation components
  • Positive screening test for ethanol or other drugs of abuse
  • Unable to receive medications intranasally

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
diazepam nasal spray (Adults)diazepam nasal sprayOne dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
Diazepam Nasal Spray (Adolescents)diazepam nasal sprayOne dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
Primary Outcome Measures
NameTimeMethod
Olfactory Changes as Measured by the Smell Identification Test (SIT)Screening, weeks 12, 24, 36, 48 and 51

The SIT is a 50-item multiple-choice standardized test of olfactory function. Scoring of the test in the ability to smell ranges from normal (Normosmia: score 35 - 40 Women; 34 - 40 Men); to inability to smell (Anosmia score 6 - 18); or Malingering (not engaged in the test) ranges 0 - 5.

Change From Baseline (Screening) in Nasal Mucosa.Screening, Weeks 12, 24, 36, 48 and 51

Change from baseline treatment visits using a focused nasal exam was based on a scale of nasal irritation "none" to Grade 4 "septal perforation."

Change in Taste as Measured by a Taste Change QuestionnaireWeeks 12, 24

Change in taste questionnaire was administered to subjects at every study visit only if the subject complained of a change in taste or as needed to report a related AE. The taste change profile included sweet, salty, sour, bitter, oily, sharp, chalky, metallic. The subject rated the change on a 10-point scale ranging from a weak change (1) to very strong (10).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (33)

Acorda Site #237

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Acorda Site #231

๐Ÿ‡บ๐Ÿ‡ธ

Tallahassee, Florida, United States

Acorda Site #202

๐Ÿ‡บ๐Ÿ‡ธ

Bethesda, Maryland, United States

Acorda Site #217

๐Ÿ‡บ๐Ÿ‡ธ

Augusta, Georgia, United States

Acorda Site #235

๐Ÿ‡บ๐Ÿ‡ธ

Memphis, Tennessee, United States

Acorda Site #222

๐Ÿ‡บ๐Ÿ‡ธ

Hackensack, New Jersey, United States

Acorda Site #224

๐Ÿ‡บ๐Ÿ‡ธ

Renton, Washington, United States

Acorda Site #241

๐Ÿ‡บ๐Ÿ‡ธ

Port Charlotte, Florida, United States

Acorda Site #221

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

Acorda Site #227

๐Ÿ‡บ๐Ÿ‡ธ

Phoenix, Arizona, United States

Acorda Site #204

๐Ÿ‡บ๐Ÿ‡ธ

Little Rock, Arkansas, United States

Acorda Site #203

๐Ÿ‡บ๐Ÿ‡ธ

Charleston, South Carolina, United States

Acorda Site #206

๐Ÿ‡บ๐Ÿ‡ธ

Orlando, Florida, United States

Acorda Site #220

๐Ÿ‡บ๐Ÿ‡ธ

Orange, California, United States

Acorda Site #223

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Acorda Site #232

๐Ÿ‡บ๐Ÿ‡ธ

Honolulu, Hawaii, United States

Acorda Site #213

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Acorda Site #218

๐Ÿ‡บ๐Ÿ‡ธ

Nashville, Tennessee, United States

Acorda Site #219

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Acorda Site #225

๐Ÿ‡บ๐Ÿ‡ธ

Fort Wayne, Indiana, United States

Acorda Site #208

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Acorda Site #230

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

Acorda Site #229

๐Ÿ‡บ๐Ÿ‡ธ

Houston, Texas, United States

Acorda Site #205

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis, Missouri, United States

Acorda Site #233

๐Ÿ‡บ๐Ÿ‡ธ

Rochester, New York, United States

Acorda Site #212

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Acorda Site #210

๐Ÿ‡บ๐Ÿ‡ธ

Madison, Wisconsin, United States

Acorda Site #215

๐Ÿ‡บ๐Ÿ‡ธ

Richmond, Virginia, United States

Acorda Site #226

๐Ÿ‡บ๐Ÿ‡ธ

Ames, Iowa, United States

Acorda Site #234

๐Ÿ‡บ๐Ÿ‡ธ

Tampa, Florida, United States

Acorda Site #201

๐Ÿ‡บ๐Ÿ‡ธ

Tampa, Florida, United States

Acorda Site #216

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Missouri, United States

Acorda Site #214

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath